Skip to main content

Mark Kosinski, DPM, FIDSA, MA

04/20/2011
Given the prevalence of onychomycosis and the emergence of laser therapy, these panelists review their approaches to managing onychomycosis, discuss ethical considerations with non-FDA approved modalities and emphasize the importance of...
Given the prevalence of onychomycosis and the emergence of laser therapy, these panelists review their approaches to managing onychomycosis, discuss ethical considerations with non-FDA approved modalities and emphasize the importance of...
Given the prevalence of...
04/20/2011
Podiatry Today
Education
10/03/2003
The common thread shared by virtually all antibiotics relevant to podiatry is their activity against S. aureus. After all, S. aureus is by far the predominant infecting organism in lower extremity skin and skin structure infections. The...
The common thread shared by virtually all antibiotics relevant to podiatry is their activity against S. aureus. After all, S. aureus is by far the predominant infecting organism in lower extremity skin and skin structure infections. The...
The common thread shared by...
10/03/2003
Podiatry Today
Diabetes Watch
09/22/2009
   Diabetic foot osteomyelitis continues to be one of the more challenging entities to diagnose and treat accurately. Although there are established clinical practice guidelines set forth by the Infectious Diseases Society of America (IDSA),...
   Diabetic foot osteomyelitis continues to be one of the more challenging entities to diagnose and treat accurately. Although there are established clinical practice guidelines set forth by the Infectious Diseases Society of America (IDSA),...
   Diabetic foot osteomyelitis...
09/22/2009
Podiatry Today
Diabetes Watch
12/03/2005
   Many exciting antibiotics have either recently been approved, received a new FDA indication or will soon become available. Some are well known and have already been incorporated into clinical practice. Many are the first in their...
   Many exciting antibiotics have either recently been approved, received a new FDA indication or will soon become available. Some are well known and have already been incorporated into clinical practice. Many are the first in their...
   Many exciting antibiotics...
12/03/2005
Podiatry Today